[1]Xu K, Li B, Zhang S, et al. DCZ3301, an aryl-guanidino agent, inhibits ocular neovascularization via PI3K/AKT and ERK1/2 signaling pathways[J]. Exp Eye Res, 2020, 201:108267.doi: 10.1016/j.exer.2020.108267.
[2]Zheng Y, Liu Y, Wang L, et al. MicroRNA-126 suppresses the proliferation and migration of endothelial cells in experimental diabetic retinopathy by targeting polo-like kinase 4[J]. Int J Mol Med, 2021, 47:151-160.
[3]Chakravarthy U, Havilio M, Syntosi A, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD[J]. Eye (Lond), 2021. doi: 10.1038/s41433-020-01354-4.
[4]Yin X, Lin X, Ren X, et al. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating uni-que gene sets[J]. Pharmacol Res, 2019, 146:104277. doi: 10.1016/j.phrs.2019.104277.
[5]Angermann R, Rauchegger T, Nowosielski Y, et al. Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanism[J]. Acta Ophthalmol, 2020. doi: 10.1111/aos.14691.
[6]Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema[J]. Ophthalmology, 2019, 126:1155-1170.
[7]Ding K, Eaton L, Bowley D, et al. Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration[J]. MAbs, 2017, 9:269-284.
[8]Liu Y, Feng M, Cai J, et al. Repurposing bortezomib for choroidal neovascularization treatment via antagonizing VEGF-A and PDGF-D mediated signaling[J]. Exp Eye Res, 2021, 204:108446. doi: 10.1016/j.exer.2021.108446.
[9]Li Y, Hu D, Lv P, et al. Expression of platelet-derived growth factor-C in aqueous humor of patients with neovascular glaucoma and its correlation with vascular endothelial growth factor[J]. Eur J Ophthalmol, 2020, 30:500-505.
[10]Miwa Y, Hoshino Y, Shoda C, et al. Pharmacological HIF inhibition prevents retinal neovascularization with improved visual function in a murine oxygen-induced retinopathy model[J]. Neurochem Int, 2019, 128:21-31.
[11]Zeng M, Shen J, Liu Y, et al. The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization[J]. J Mol Med (Berl), 2017, 95:417-429.
[12]Sheibani N, Wang S, Darjatmoko SR, et al. Novel anti-angiogenic PEDF-Derived small peptides mitigate, choroidal neovascularization[J]. Exp Eye Res, 2019, 188:107798. doi: 10.1016/j.exer.2019.107798.
[13]Kim HW, Roh KH, Kim SW, et al. Type I pig collagen enhances the efficacy of PEDF 34-mer peptide in a mouse model of laser-induced choroidal neovascularization[J]. Graefes Arch Clin Exp Ophthalmol, 2019, 257:1709-1717.
[14]Zhang X, Wu J, Wu C, et al. Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection[J]. Diabetes Res Clin Pract, 2020, 162:108083. doi: 10.1016/j.diabres.2020.108083.
[15] Lazzara F, Fidilio A, Platania CBM, et al. Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway[J]. Biochem Pharmacol, 2019, 168: 341-351.
[16] Dong Z, Santeford A, Ban N, et al. FGF2-induced STAT3 activation regulates pathologic neovascularization[J]. Exp Eye Res,2019, 187:107775. doi: 10.1016/j.exer.2019.107775.
[17]Hosaka K, Yang Y, Nakamura M, et al. Dual roles of endothelial FGF-2-FGFR1-PDGF-BB and perivascular FGF-2-FGFR2-PDGFRβ signaling pathways in tumor vascular remodeling[J]. Cell Discov, 2018, 4:3. doi: 10.1038/s41421-017-0002-1.
[18]Lee SHS, Chang H, Kim HJ, et al. Effects of Stuffer DNA on the suppression of choroidal neovascularization by a rAAV expressing a mTOR-inhibiting shRNA[J]. Mol Ther Methods Clin Dev, 2019, 14:171-179.
[19]Wang C, Ma J, Xu M, et al. mTORC1 signaling pathway regulates macrophages in choroidal neovascularization[J]. Mol Immunol,2020, 121:72-80.
[20]Terao R, Honjo M, Totsuka K,et al. The role of sphingosine 1-phosphate receptors on retinal pigment epithelial cells barrier function and angiogenic effects[J]. Prostaglandins Other Lipid Mediat, 2019, 145:106365. doi: 10.1016/j.prostaglandins.2019.106365.
[21]Arnst KE, Wang Y, Hwang DJ,et al. A potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance[J]. Cancer Res, 2018, 78:265-277. |
